ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Cardiovascular"

  • Abstract Number: 1016 • ACR Convergence 2022

    Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis

    Ivan Arias-de la Rosa1, Elena Carnero-Montoro2, lourdes Ladehesa-Pineda3, Clementina Lopez-Medina4, Rafaela Ortega-Castro1, Maria del Carmen Abalos-Aguilera5, Daniel Dominguez-Toro6, Manuel Martinez-Bueno2, Ruth Dominguez6, Olivia Castellini6, Guillermo Barturen2, Chary López-Pedrera7, Eduardo Collantes1, Marta Alarcon-Riquelme2 and Nuria Barbarroja1, 1IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba, Spain, 2Center for Genomics and Oncological Research (GENYO), Granada, Spain, 3Reina Sofia University Hospital/Rheumatology Department/Maimonides Institute for Biomedical Research (IMIBIC), Cordoba, Spain, 4Reina Sofia University Hospital, Rheumatology Department, Jaén, Spain, 5Hospital Universitario Reina Sofia, Cordoba, Spain, 6GENYO. Centre for Genomics and Oncological Research: Pfizer, University of Granada, Andalusian Regional Government, PTS Granada, Granada, Spain, 7Maimonides Institute for Biomedical Research of Córdoba, Cordoba, Spain

    Background/Purpose: Traditional cardiovascular disease (CVD) risk factors could be underestimating the subclinical atherosclerosis in patients with Spondyloarthritis (SpA). The identification of subclinical CVD sings and…
  • Abstract Number: 1429 • ACR Convergence 2022

    Acute Cardiovascular Events Risk in Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION Study

    jacques-eric gottenberg1, Nadir Mammar2, Meriem Kessouri2, Jeremie RUDANT2, nada Assi3, Benjamin grenier3 and julien kirchgesner4, 1Strasbourg University Hospital, Strasbourg, France, 2Pfizer, Paris, France, 3HEVA, Lyon, France, 4AP-HP, Paris, France

    Background/Purpose: Patients with IMID, and notably patients with rheumatoid arthritis (RA), are at increased risk of major adverse cardiovascular event (MACE) compared with the general…
  • Abstract Number: 1645 • ACR Convergence 2022

    Evaluating the Use of Genetic Risk Scores as Part of an Integrated Risk Tool for Predicting Coronary Artery Disease in Patients with Rheumatoid Arthritis

    Mehreen Soomro1, Michael Stadler1, Sebastien Viatte1, Alex Macgregor2, Suzanne Verstappen1, Anne Barton1 and John Bowes1, 1The University of Manchester, Manchester, United Kingdom, 2The University of East Anglia, Norwich, United Kingdom

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a higher prevalence of coronary artery disease (CAD) than the general population, which contributes to early mortality. However,…
  • Abstract Number: 1966 • ACR Convergence 2022

    Favorable Effects of TNF Inhibitors on Intima Media Thickness and Arterial Stiffness in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Eva van Geel1, Bafrin Abdulmajid1, Annelies Blanken2 and Michael Nurmohamed3, 1Reade Rheumatology Center, Amsterdam, Netherlands, 2Amsterdam University Medical Centers, Amsterdam, Netherlands, 3Amsterdam University Medical Center, Kortenhoef, Netherlands

    Background/Purpose: Controlling inflammation with tumour necrosis factor (TNF) inhibitors in rheumatoid arthritis (RA) patients is hypothesized to reduce their cardiovascular risk. Arterial wall thickness (carotid…
  • Abstract Number: 0384 • ACR Convergence 2022

    Inflammation Is Associated with Incident Hypertension in Patients with Axial Spondyloarthritis: A Longitudinal Cohort Study

    Jenny Lin Hong Shi1, Steven H Lam2, Ho So3, Edmund Li1, Tena Li1, Cheuk Chun Szeto1 and Lai-shan Tam1, 1The Chinese University of Hong Kong, Hong Kong, China, 2The Chinese university of Hong Kong, Hong Kong, Hong Kong, 3The Faculty of Medicine, CUHK, Hong Kong, Hong Kong

    Background/Purpose: In the general population, hypertension (HT) is reported as one of the most important risk and modifiable factors to develop CVD. It is well…
  • Abstract Number: 0722 • ACR Convergence 2022

    Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry

    Alejandro Brigante1, Rosana Quintana2, Carolina Isnardi3, Karen Roberts4, Gimena Gomez5, Maria Haye Salinas6, Enrique Soriano7, Guillermo Pons-Estel8, Maria De la Vega8, Osvaldo kerzberg7, Julieta Gamba7, Anastasia Secco9, Gustavo Citera10, Cesar Graf7, Veronica Savio11, Maria de los Angeles Gallardo7, Nora Aste7, Mercedes A Garcia12, Gustavo Casado7, Carla Gobbi7, Graciela Gomez7, Joan Manuel Dapeña13, Guillermo Berbotto7, Malena Viola7, Jonathan Rebak7, Diana Dubinsky7, Veronica Saurit14, Ingrid Petkovic7, Ana Bertoli7, Erika Catay7, C Leoni7, Ida Elena Exeni7, Bernardo Pons-Estel15, Sergio Paira7, GH Bovea Castelblanco7, Mercedes De la Sota7, Dora Pereira7, Gustavo Medina7, Amelia Granel7, Maria s Larroude7, Analia Patricia Alvarez7, Santiago Agüero16, Cecilia Pisoni17, Monica Sacnun7 and Edson Velozo18, 1UNISAR, Lobos, Argentina, 2Centro Regional de Enfermedades Autoinmunes y Reumáticas. Grupo Oroño (GO CREAR) and Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 3SAR-COVID Coordinator, Research Unit Argentine Society of Rheumatology, Buenos Aires, Argentina, 4UNISAR, Rosario, Argentina, 5Sanatorio Guemes, Buenos Aires, Argentina, 6UNLAR, La Rioja, Argentina, 7On behalf of the BIOBADASAR 3.0 registry, Buenos Aires, Argentina, 8Argentine Society of Rheumatology, Buenos Aires, Argentina, 9Rivadavia Hospital, Buenos Aires, Argentina, 10Instituto de Rehabilitación Psicofísica (IREP), Buenos Aires, Argentina, 11Hospital Córdoba; Consultora Integral de Salud CMP, Cordoba, Argentina, 12HIGA San Martin, La Plata, Argentina, 13Hospital General de Agudos Dr. Enrique Tornu, Buenos Aires, Argentina, 14Hospital Privado Universitario, Cordoba, Argentina, 15Grupo Oroño - Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina, 16Centro de Rehabilitación Dr Mauricio Figueroa, Catamarca, Argentina, 17CEMIC- Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina, 18SAR COVID Investigator, Caba

    Background/Purpose: Major adverse cardiovascular events (MACE) and neoplasms are a concern in autoimmune diseases. RA and PsA are diseases where inflammation plays a key role…
  • Abstract Number: 1057 • ACR Convergence 2022

    Usefulness of REVEAL 2.0 Score as a Prognosis Tool of All-Cause Pulmonary Hypertension in Systemic Sclerosis Patients: A Multicentric Study

    Ivette Casafont-Solé1, Laura Calvo2, Anne Riveros-Frutos3, Carlos De la Puente Bujidos4, Pau Alcubilla5, Lourdes Mateo1 and Ivan Castellví6, 1Hospital Universitari Germans Trias i Pujol, Badalona, Spain, 2Hospital Universitario Ramon y Cajal, Madrid, Spain, 3Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, 4Ramon y Cajal University Hospital, Madrid, Spain, 5Hospital Clínic de Barcelona, Barcelona, Spain, 6Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain

    Background/Purpose: Pulmonary arterial hypertension (PAH) leads to a progressive right heart failure and death.PAH is a leading cause of death in Systemic Sclerosis (SSc). To…
  • Abstract Number: 1442 • ACR Convergence 2022

    Role of Platelet-bound Complement Activation Product (PC4d) in Predicting Risk of Future Thrombotic Events in Systemic Lupus Erythematosus

    Anca Askanase1, John Conklin2, Michelle Petri3, Vasileios Kyttaris4, Yevgeniya Gartshteyn5, Wei Tang1, Anja Kammesheidt6 and Roberta Alexander2, 1Columbia University Medical Center, New York, NY, 2Exagen, Inc., Vista, CA, 3Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Columbia University Medical Center, Glen Rock, NJ, 6self, Laguna Beach, CA

    Background/Purpose: Platelet-bound complement activation products (PC4d) are associated with a history of thrombosis in systemic lupus erythematosus (SLE) (Gartshteyn al., 2021; Petri et al., 2017).…
  • Abstract Number: 1648 • ACR Convergence 2022

    Risk of Vascular Events Under the Treatments with Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: An Analysis Using Japanese Health Insurance Database

    Eiichi Tanaka1, Ryoko Sakai2, Eisuke Inoue3 and Masayoshi Harigai1, 1Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 2Meiji Pharmaceutical University, Tokyo, Japan, 3Research Administration Center, Showa University, Shinagawa-ku, Japan

    Background/Purpose: Janus kinase inhibitors (JAKIs) have shown positive therapeutic impacts on treatments for rheumatoid arthritis (RA), whereas, concerns have been raised about the risk of…
  • Abstract Number: 1976 • ACR Convergence 2022

    Outcomes of the First Episode of STEMI in Rheumatoid Arthritis from the National Inpatient Sample Database 2016-2019

    Amar Suwal1, Biraj Shrestha2, Ibiyemi Oke2 and Anthony Donato2, 1Reading Hospital, Tower Health, Reading, PA, 2reading hospital- tower health, Reading, PA

    Background/Purpose: Patients with Rheumatoid arthritis (RA) have a higher burden of cardiovascular diseases (CVDs) than the general population, with most deaths resulting from myocardial infarctions.…
  • Abstract Number: 0415 • ACR Convergence 2022

    The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events in Ankylosing Spondylitis

    Jean Liew1, Timothy Treu2, yojin Park2, Jacqueline Ferguson3, Morgan Rosser2, yuk-Lam Ho2, Susan Heckbert4, Lianne Gensler5, Katherine Liao6 and Maureen Dubreuil7, 1Boston University School of Medicine, Boston, MA, 2VA Boston Healthcare System, Boston, MA, 3Stanford, Palo Alto, CA, 4University of Washington, Seattle, WA, 5Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, 6Brigham and Women's Hospital, Boston, MA, 7Department of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: The increased cardiovascular (CV) disease burden in ankylosing spondylitis (AS) is established. Whether tumor necrosis factor inhibitor (TNFi) treatment, particularly when started early in…
  • Abstract Number: 0885 • ACR Convergence 2022

    Association Between Changes in Inflammatory Pathways Associated with a Reduction in CV Risk: Results from the LiiRA Study

    brittany weber1, Dana Weisenfeld1, Thany Seyok1, Elena Massarotti1, Selena Huang1, Derrick Todd1, Jonathan Coblyn1, michael weinblatt1, Tianrun Cai1, Kumar Dahal1, leanne BArrett1, Daniel Solomon1, Jorge Plutzky1, Marcy Bolster2, marcelo Dicarli1 and Katherine Liao1, 1Brigham and Women's Hospital, Boston, MA, 2Massachusetts General Hospital, Boston, MA

    Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased cardiovascular (CV) risk. Coronary flow reserve (CFR) is a quantitative imaging biomarker of CV risk that…
  • Abstract Number: 1058 • ACR Convergence 2022

    Clinical Characteristics and Survival of Combined Pulmonary Arterial Hypertension and Interstitial Lung Disease in Systemic Sclerosis

    Jessica Fairley1, Dylan Hansen2, Laura Ross3, Susanna Proudman4, Jo Sahhar5, Gene-Siew Ngian6, Jenny Walker7, Lauren Host8, Kathleen Morrisroe2, Diane Apostolopoulos9, Nava Ferdowsi2, Michelle Wilson9, Maryam Tabesh2, Wendy Stevens2 and Mandana Nikpour10, 1The University of Melbourne, Melbourne, Australia, 2St Vincent's Hospital Melbourne, Melbourne, Australia, 3The University of Melbourne at St. Vincent's Hospital, Brunswick, Australia, 4University of Adelaide, Medindie, Australia, 5Monash Health, Melbourne, Australia, 6Melbourne Health, Northcote, Australia, 7Royal Adelaide Hospital, Adelaide, Australia, 8Fiona Stanley Hospital, London, United Kingdom, 9Monash University, Melbourne, Australia, 10The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia

    Background/Purpose: Pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD) are the leading causes of systemic sclerosis (SSc) associated death. There is increasing interest in…
  • Abstract Number: 1454 • ACR Convergence 2022

    A High Genetic Risk of SLE Is Associated with an Increased Risk of Myocardial Infarction; A Combined Observational and Mendelian Randomization Study

    Sarah Reid1, Johanna K Sandling1, Pascal Pucholt1, Ahmed Sayadi1, Christopher Sjöwall2, Karoline Lerang3, Andreas Jönsen4, Anders A Bengtsson4, Øyvind Molberg3, Anna Rudin5, Solbritt Rantapää-Dahlqvist6, Lars Ronnblom7 and Dag Leonard1, 1Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Department of Biomedical and Clinical Sciences, Division of Inflammation and Infection, Linköping University, Linköping, Sweden, 3Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 4Department of Clinical Sciences, Lund, Section for Rheumatology, Lund University, Lund and Skåne University Hospital, Lund, Sweden, 5Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy of University of Gothenburg, Gothenburg, Sweden, 6Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden, 7Uppsala University, Uppsala, Sweden

    Background/Purpose: The reasons for the high cardiovascular morbidity in patients with SLE are not fully understood. Here, we combine a mendelian randomization (MR) approach and…
  • Abstract Number: 1649 • ACR Convergence 2022

    Five-Year Cardiovascular Event Risk in Early Rheumatoid Arthritis Patients Who Received Treat-to-Target Management

    Lai-shan Tam1, Tsz On Lam2 and Man Choi Wan3, 1The Chinese University of Hong Kong, Hong Kong, China, 2Prince of Wales Hospital, Hong Kong, Hong Kong, 3Ruttonjee Hospital, Hong Kong, Hong Kong, Hong Kong

    Background/Purpose: Rheumatoid arthritis (RA) is known to cause increased risk of cardiovascular (CV) disease (CVD) due to the underlying inflammation. The year of 2010 revolutionised…
  • « Previous Page
  • 1
  • …
  • 16
  • 17
  • 18
  • 19
  • 20
  • …
  • 31
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology